NEW YORK, July 27, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of IntelliPharmaCeutics International Inc. ("IntelliPharmaCeutics" or the "Company") (NASDAQ: IPCI). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ipci.
The investigation concerns whether IntelliPharmaCeutics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 26, 2017, IntelliPharma revealed that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration ("FDA") voted 22 to 1 against approving IntelliPharma's New Drug Application for Rexista extended release tablets, an opioid painkiller. The FDA also voted that Rexista had not demonstrated properties than can be expected to deter abuse by the intravenous route, and that there was insufficient data to support "inclusion of language regarding abuse-deterrent properties in the product label for the intravenous route of administration." Following this news, IntelliPharma stock dropped as much as $1.19 per share, or 47.6%, during intraday trading on July 27, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of IntelliPharmaCeutics, you can assist this investigation by visiting the firm's site: www.bgandg.com/ipci. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC